SHATTUCK LABS INC · Data as of 2026-09-08
in 2027
We expect to share additional pre-clinical data, including data from our ongoing non-human primate toxicology study for SL-846, in the second half of 2026, and to share initial Phase 1 clinical data for SL-846 in 2027.Source filing
H1 2028
Data from the induction portion of the trial are expected in the first half of 2028.Source filing
Oct 17–Oct 20
• Preclinical data for SL-846, including safety, pharmacokinetics, and receptor occupancy from the ongoing GLP toxicology study are expected to be presented in a poster at UEG Week, to be held October 17-20, 2026.Source filing